12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Colobreathe colistimethate sodium regulatory update

The U.K.'s NICE issued final guidance recommending Colobreathe colistimethate sodium from Forest to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis (CF) patients if nebulized colistimethate, a generic antibiotic, is...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >